Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naxitamab and GM-CSF with Induction Chemotherapy in High-Risk Neuroblastoma
NCT07537400Phase 2Recruiting
- Sponsor
- Shaare Zedek Medical Center
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of naxitamab in neuroblastoma, sponsored by Shaare Zedek Medical Center. Started Jun 2026; status: recruiting.
02
Drugs
naxitamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT07537400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537400.